Portal de Periódicos da CAPES

A National Strategy for the Elimination of Viral Hepatitis Emphasizes Prevention, Screening, and Universal Treatment of Hepatitis C

2017; American College of Physicians; Volume: 166; Issue: 12 Linguagem: Inglês

10.7326/m17-0766

1539-3704

Gillian J. Buckley, Brian L. Strom,

Liver Disease Diagnosis and Treatment

Ideas and Opinions20 June 2017A National Strategy for the Elimination of Viral Hepatitis Emphasizes Prevention, Screening, and Universal Treatment of Hepatitis CGillian J. Buckley, PhD, MPH and Brian L. Strom, MD, MPHGillian J. Buckley, PhD, MPHFrom the National Academies of Sciences, Engineering, and Medicine, Washington, DC, and Rutgers University, The State University of New Jersey, Newark, New Jersey. and Brian L. Strom, MD, MPHFrom the National Academies of Sciences, Engineering, and Medicine, Washington, DC, and Rutgers University, The State University of New Jersey, Newark, New Jersey.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M17-0766 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A consensus committee of the National Academies of Sciences, Engineering, and Medicine is proposing a strategy to eliminate hepatitis B and C as public health problems in the United States (1). Implementation of the recommendations could pay back handsomely, averting a cumulative total of about 90 000 viral hepatitis deaths by 2030 and reducing the incidence of hepatitis C by 90%.A 2016 report from the same committee concluded that there were substantial obstacles to meeting this goal (2). The new report presents specific actions to hasten the end of these diseases and outlines 5 areas—information, interventions, service delivery, financing, and ...References1. National Academies of Sciences, Engineering,and Medicine. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. Washington, DC: National Academies Pr; 2017. doi:10.17226/24731 CrossrefGoogle Scholar2. National Academies of Sciences, Engineering,and Medicine. Eliminating the Public Health Problem of Hepatitis B and C in the United States: Phase One Report. Washington, DC: National Academies Pr; 2016. doi:10.17226/23407 CrossrefGoogle Scholar3. Moyer VA; U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-57. [PMID: 23798026]. doi:10.7326/0003-4819-159-5-201309030-00672 LinkGoogle Scholar4. Linas BP, Hu H, Barter DM, Horberg M. Hepatitis C screening trends in a large integrated health system. Am J Med. 2014;127:398-405. [PMID: 24486288] doi:10.1016/j.amjmed.2014.01.012 CrossrefMedlineGoogle Scholar5. Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al; Centers for Disease Control and Prevention (CDC). Surveillance of vaccination coverage among adult populations—United States, 2014. MMWR Surveill Summ. 2016;65:1-36. [PMID: 26844596] doi:10.15585/mmwr.ss6501a1 CrossrefMedlineGoogle Scholar6. Yusuf HR, Daniels D, Smith P, Coronado V, Rodewald L. Association between administration of hepatitis B vaccine at birth and completion of the hepatitis B and 4:3:1:3 vaccine series. JAMA. 2000;284:978-83. [PMID: 10944643] CrossrefMedlineGoogle Scholar7. Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M. National, state, and selected local area vaccination coverage among children aged 19-35 months—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:889-96. [PMID: 26313470] CrossrefMedlineGoogle Scholar8. Project ECHO: Our story [video]. Albuquerque: Univ of New Mexico; 2011. Accessed at http://echo.unm.edu/about-echo/our-story/ on 2 November 2016. Google Scholar9. Lo Re V, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, et al. Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol. 2016;14:1035-43. [PMID: 27062903] doi:10.1016/j.cgh.2016.03.040 CrossrefMedlineGoogle Scholar10. Beckman AL, Bilinski A, Boyko R, Camp GM, Wall AT, Lim JK, et al. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff (Millwood). 2016;35:1893-1901. [PMID: 27702964] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From the National Academies of Sciences, Engineering, and Medicine, Washington, DC, and Rutgers University, The State University of New Jersey, Newark, New Jersey.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-0766.Corresponding Author: Gillian J. Buckley, PhD, MPH, National Academies of Sciences, Engineering, and Medicine, 500 Fifth Street NW, Washington, DC 20001; e-mail, [email protected]edu.Current Author Addresses: Dr. Buckley: National Academies of Sciences, Engineering, and Medicine, 500 Fifth Street NW, Washington, DC 20001.Dr. Strom: Rutgers Biomedical and Health Sciences, Rutgers University, The State University of New Jersey, 65 Bergen Street, Suite 1535, Newark, NJ 07107.Author Contributions: Conception and design: B.L. Strom.Analysis and interpretation of the data: B.L. Strom.Drafting of the article: G.J. Buckley, B.L. Strom.Critical revision for important intellectual content: B.L. Strom.Final approval of the article: G.J. Buckley, B.L. Strom.This article was published at Annals.org on 4 April 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byIntegrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination EffortsAssociation of Referral Source and Substance Use with Hepatitis C Virus Outcomes at a Southern Academic Medical CenterNationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in KoreaProgress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San FranciscoDirect‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis CMicro‐elimination of hepatitis C through testing of Egyptian pregnant women presenting at delivery: implications for screening policiesHepatitis C eradication with direct-acting anti-virals reduces the risk of variceal bleedingA Multi-Fidelity Rollout Algorithm for Dynamic Resource Allocation in Population Disease ManagementHepatitis CRetrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan NativesRandomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugsTreatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treatedBarriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinicThe Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South TexasHepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of CareDirect acting antivirals for patients without advanced liver disease: All for treatment and treatment for all?Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016Eliminación del virus de la hepatitis C en España: un reto pendienteElimination of hepatitis C virus in Spain: A pending challengeHepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physiciansHuman Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be SignificantCuring Hepatitis C Virus Infection: Best Practices From the U.S. Department of Veterans AffairsPamela S. Belperio, PharmD, Maggie Chartier, PsyD, MPH, David B. Ross, MD, PhD, MBI, Poonam Alaigh, MD, and David Shulkin, MDMaking Do With What We HaveCamilla S. Graham, MD, MPHHearing From the Silent EpidemicAlfred DeMaria Jr., MDEthnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans 20 June 2017Volume 166, Issue 12Page: 895-896KeywordsAntiviralsBirthHepatitis AHepatitis BHepatitis CInfectious hepatitisPatient advocacyPrevention, policy, and public healthRural areasVaccines ePublished: 4 April 2017 Issue Published: 20 June 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...